Table 4.
The relationship between MTDH expression and clinical variables of HCC from TCGA data
| Variable | Total (n) | Z | P value |
|---|---|---|---|
| History of other malignancy | -1.673 | 0.094 | |
| Yes | 35 | ||
| No | 324 | ||
| History of neoadjuvant treatment | -0.307 | 0.758 | |
| No | 357 | ||
| Yes | 2 | ||
| Tumor status | -0.595 | 0.552 | |
| Tumor free | 227 | ||
| With tumor | 108 | ||
| Relative family history cancer | 0.000 | 1.000 | |
| No | 203 | ||
| Yes | 107 | ||
| Radiation therapy adjuvant | -0.074 | 0.941 | |
| No | 232 | ||
| Yes | 4 | ||
| Pharmaceutical tx adjuvant | -0.338 | 0.736 | |
| No | 218 | ||
| Yes | 13 | ||
| Post-op ablation embolization | -1.350 | 0.177 | |
| No | 224 | ||
| Yes | 13 | ||
| No History of Primary Risk Factors | -1.456 | 0.145 | |
| “-” | 255 | ||
| “+” | 85 | ||
| Alcohol consumption | -0.863 | 0.388 | |
| “-” | 223 | ||
| “+” | 117 | ||
| Hemochromatosis | -0.604 | 0.546 | |
| “-” | 336 | ||
| “+” | 4 | ||
| Hepatitis B | -1.603 | 0.109 | |
| “-” | 237 | ||
| “+” | 103 | ||
| Hepatitis C | -1.093 | 0.274 | |
| “-” | 286 | ||
| “+” | 54 | ||
| Non-Alcoholic Fatty Liver Disease | -0.237 | 0.813 | |
| “-” | 320 | ||
| “+” | 20 | ||
| Smoking | -0.222 | 0.825 | |
| “-” | 323 | ||
| “+” | 17 | ||
| Cirrhosis | -0.142 | 0.887 | |
| “-” | 334 | ||
| “+” | 6 | ||
| Age | -1.043 | 0.297 | |
| ≤60 | 165 | ||
| ≥60 | 193 | ||
| Gender | -4.154 | <0.001 | |
| Male | 243 | ||
| Female | 116 | ||
| Race | 4,231 | 0.238 | |
| Asian | 156 | ||
| White | 174 | ||
| Black or African American | 17 | ||
| American Indian or Alaska native | 2 | ||
| Ethnicity | -0.160 | 0.873 | |
| Hispanic or Latino | 18 | ||
| Not Hispanic or Latino | 325 | ||
| Histological type | -2.163 | 0.031 | |
| HCC | 359 | ||
| Non-HCC liver cancers | 40 | ||
| Grade | 3.697 | 0.296 | |
| G1 | 53 | ||
| G2 | 171 | ||
| G3 | 119 | ||
| G4 | 11 | ||
| Grade 2 | -1.548 | 0.122 | |
| GI-II | 224 | ||
| GIII-IV | 130 | ||
| AJCC Pathologic T | 4.012 | 0.675 | |
| T1 | 176 | ||
| T2 | 90 | ||
| T3 | 43 | ||
| T3a | 28 | ||
| T3b | 6 | ||
| T4 | 13 | ||
| Tx | 1 | ||
| AJCC Pathologic T2 | 3.479 | 0.481 | |
| T1 | 176 | ||
| T2-T2c | 90 | ||
| T3-T3c | 77 | ||
| T4-T4c | 13 | ||
| Tx | 1 | ||
| AJCC Pathologic T3 | 1.857 | 0.395 | |
| T0 Tx | 1 | ||
| T1 | 176 | ||
| T2-4 | 180 | ||
| AJCC Pathologic N | 1.177 | 0.555 | |
| N0 | 243 | ||
| N1 | 3 | ||
| Nx | 112 | ||
| AJCC Pathologic M | 0.103 | 0.950 | |
| M0 | 258 | ||
| M1 | 4 | ||
| Mx | 97 | ||
| Pathologic Stage | 5.477 | 0.484 | |
| Stage I | 167 | ||
| Stage II | 82 | ||
| Stage III | 3 | ||
| Stage IIIA | 62 | ||
| Stage IIIB | 8 | ||
| Stage IIIC | 9 | ||
| Stage IV | 2 | ||
| Pathologic Stage 2 | 4.077 | 0.253 | |
| Stage I | 167 | ||
| Stage II | 82 | ||
| Stage III ABC | 82 | ||
| Stage IV | 2 | ||
| Pathologic Stage 3 | -0.788 | 0.430 | |
| Stage I-II | 249 | ||
| Stage III-IV | 84 | ||
| Vascular invasion | 0.580 | 0.748 | |
| None | 200 | ||
| Micro | 89 | ||
| Macro | 14 | ||
| Vascular invasion 2 | -0.754 | 0.451 | |
| No | 200 | ||
| Yes | 103 | ||
| Residual tumor | 4.295 | 0.231 | |
| R0 | 317 | ||
| R1 | 14 | ||
| R2 | 1 | ||
| Rx | 22 | ||
| Ishak fibrosis score | 3.440 | 0.487 | |
| 0-no fibrosis | 72 | ||
| 1,2-portal fibrosis | 31 | ||
| 3,4-fibrous septa | 28 | ||
| 5-nodular formation and incomplete cirrhosis | 9 | ||
| 6-established cirrhosis | 70 | ||
| Child-Pugh classification grade | 0.489 | 0.783 | |
| A | 205 | ||
| B | 19 | ||
| C | 1 |
Independent samples tests were used to evaluate the difference of MTDH expression between groups of clinical variables. A two-tailed P value <0.05 was regarded to be statistically significant.